SINOPIA BIOSCIENCES INC
San Diego, CA · Biotech · Private
Small molecule therapeutic (SB-0107) for Parkinson's disease and levodopa-induced complications, discovered using a computational drug discovery platform
sinopiabio.com →- Grants
- $20M
- 28 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 4 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Improving safety and efficacy of platelet transfusion through systems biology | $223,582 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving safety and efficacy of platelet transfusion through systems biology | $223,582 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Improving red blood cell transfusion through systems biology | $1,029,290 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Improving red blood cell transfusion through systems biology | $1,472,641 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a Systems Biology Platform for Predicting Drug Toxicity and Safety | $190,634 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving red blood cell transfusion through systems biology | $443,351 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving safety and efficacy of platelet transfusion through systems biology | $1,099,022 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving safety and efficacy of platelet transfusion through systems biology | $1,527,749 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving safety and efficacy of platelet transfusion through systems biology | $428,727 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery | $442,427 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving safety and efficacy of platelet pathogen inactivation techniques through systems biology | $224,284 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving safety and efficacy of platelet pathogen inactivation techniques through systems biology | $224,284 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a systems biology platform for predicting, preventing, and treating drug side effects | $802,538 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a systems biology platform for predicting, preventing, and treating drug side effects | $754,478 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery | $1,335,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a novel therapeutic for Parkinson's disease | $577,562 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery | $871,587 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical assessment of a novel compound for treating radiation-induced oral mucositis | $318,284 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a novel therapeutic for Parkinson's disease | $1,561,760 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a novel therapeutic for Parkinson's disease | $1,461,860 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a novel therapeutic for Parkinson's disease | $99,900 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a novel therapeutic for Parkinson's disease | $1,282,299 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and validation of data standards and computational methods for large scale metabolomics data analysis for data driven drug discovery | $350,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical assessment of a novel compound for treating radiation-induced oral mucositis | $1,493,635 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of neural network models to enable efficient metabolomic characterization of compound libraries for data-driven drug discovery | $350,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical assessment of a novel compound for treating radiation-induced oral mucositis | $849,193 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical assessment of a novel compound for treating radiation-induced oral mucositis | $39,650 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancer | $285,599 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1708 | STOECKER MD, WILLIAM V | — | — |
| 1709 | MTI BIOTECH, INC. | — | — |
| 1710 | GISMO THERAPEUTICS INC. | — | — |
| 1711 | SINOPIA BIOSCIENCES INC | — | — |
| 1712 | NEUROGT INC | — | — |
| 1713 | Lila Sciences | — | — |
| 1714 | ARC Biotechnology LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Isotopically-labelled Trapidil Derivativesgranted
- Treating Extrapyramidal Syndrome Using Trapidilapplication
- Treating Extrapyramidal Syndrome Using Trapidilgranted
- Treating Extrapyramidal Syndrome Using Trapidilgranted
- Treating Cognitive Disorders Using Trapidilapplication
- Treating Extrapyramidal Syndrome Using Trapidilgranted
- Treating Extrapyramidal Syndrome Using Trapidilapplication
- Treating Extrapyramidal Syndrome Using Trapidilapplication
- Isotopically-labelled Trapidil Derivativesapplication
- Treating Cognitive Disorders Using Trapidilapplication
- Isotopically-labelled Trapidil Derivativesapplication
- Isotopically-labelled Trapidil Derivativesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.